Safety of SGLT2 Inhibitors and Urinary Tract Infections
Author Information
Author(s): Iordan Liana, Avram Vlad Florian, Timar Bogdan, Sturza Adrian, Popescu Simona, Albai Oana, Timar Romulus Zorin, Falhammar Henrik, Radišauskas Ričardas
Primary Institution: Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Hypothesis
Does the use of SGLT2 inhibitors increase the risk of urinary tract infections in patients with type 2 diabetes?
Conclusion
The use of SGLT2 inhibitors did not increase the likelihood of developing a urinary tract infection in this patient population.
Supporting Evidence
- Patients with higher HbA1c or BMI showed an increased predisposition to contracting UTIs.
- The female gender was associated with an increased likelihood of UTI.
- Taking SGLT2 inhibitors did not increase the risk of contracting a UTI.
Takeaway
This study found that taking a specific diabetes medication called SGLT2 inhibitors doesn't make people more likely to get urinary infections.
Methodology
A cross-sectional, noninterventional study evaluating 328 patients with type 2 diabetes admitted to a diabetes clinic.
Limitations
The study is cross-sectional and did not consider the duration of SGLT2 inhibitor use or personal hygiene aspects.
Participant Demographics
49.4% male and 50.6% female, median age 63 years, median duration of diabetes 8 years.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website